查看文章

To the Editor: We read the recent publication in Pharmacological Research on the impact of pre-admission antithrombotic therapy in coronavirus disease 2019 (COVID-19) patients with great interest [1]. A recent retrospective cohort study demonstrated that the use of heparin improved the 28-day mortality of severe COVID-19 patients at risk of sepsis-induced coagulopathy.[2] Another study found that patients who received treatment-dose anticoagulants were more likely to require invasive mechanical ventilation [3]. However, few population-based studies have examined the effects of prophylactic antithrombotic therapy on the risk of severe COVID-19. Thus, the present study aims to evaluate whether anticoagulant and anti-platelet use is associated with a lower risk of severe COVID-19 infection through a territory-wide, propensity score-matched cohort study.

Ethics approval for this study was obtained from the …